- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Marc E. Lippman, MD
Professor of Oncology and Medicine
Georgetown University Medical Center
- Seeking to understand how communication between breast cancer cells and non-cancer cells contributes to tumor progression and metastasis.
- Laboratory studies are ongoing to characterize the function of a protein called RAGE and identify other factors that may contribute to its activity in promoting metastasis.
- This work may lead to the development of novel weapons to add to the arsenal against metastatic breast cancer to extend the lives of patients.
Metastasis is the leading cause of breast cancer deaths. While treatable, it is still an incurable disease. Studies have shown that interactions between tumor cells and non-tumor cells nearby can promote tumor growth and spread. Dr. Lippman’s team has identified an important factor in mediating this process. They are conducting studies to identify strategies to leverage this discovery to improve response to chemotherapy and prevent metastasis.
Full Research Summary
Despite great strides in treatment for localized breast cancer, metastatic breast cancer remains an overwhelmingly lethal disease. Dr. Lippman's research has shown that targeting a specific protein, called RAGE, can reduce tumor growth, improve response to immunotherapy, and prevent breast cancer metastasis in laboratory models. RAGE is also an important mediator of inflammatory signaling in obesity and may prevent obesity-related breast cancer.
This year, they are testing the idea that targeting RAGE will synergize with established chemotherapeutic agents to inhibit breast cancer metastasis. The testing of RAGE inhibitors in combination with other therapies in preclinical models will represent a critical step in translating these approaches to breast cancer patients.
Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan. From 1988 through 1999 he was Professor of Medicine and Pharmacology and Chair, Department of Oncology, at Georgetown University in Washington, DC, and served as Director of the Lombardi Cancer Center. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the NIH. He completed a Fellowship in Endocrinology at Yale Medical School from 1973-1974. He was Clinical Associate at the NCI from 1970-1971 and Clinical Associate at the Laboratory of Biochemistry of the NCI. From 1970-1988 he served as an Officer and Medical Director of the United States Public Health Service. Dr. Lippman completed his residency on the Osler Medical Service, John Hopkins University Hospital from 1968-1970. He has received numerous awards including Clinical Investigator Award, American Federation for Clinical Research in 1985; Transatlantic Medal and Lecture, British Endocrine Societies, 1989; the Astwood Award, Endocrine Society, 1991; the Bernard Fisher Award, University of Pittsburgh in 1991; the AACR Rosenthal Award in April 1994, and the Brinker Award for Basic Science of the Komen Foundation in 1994.